Porto Pharmacovigilance Centre, Faculty of Medicine of the University of Porto, Porto, Portugal.
Center for Health Technology and Services Research, Associate Laboratory RISE-Health Research Network (CINTESIS@RISE), Porto, Portugal.
Drug Saf. 2024 Dec;47(12):1203-1224. doi: 10.1007/s40264-024-01470-0. Epub 2024 Aug 19.
The safety of antiviral agents in real-world clinical settings is crucial, as pre-marketing studies often do not capture all adverse events (AE). Active pharmacovigilance strategies are essential for detecting and characterising these AE comprehensively.
The aim of this study was to identify and characterise active pharmacovigilance strategies used in real-world clinical settings for patients under systemic antiviral agents, focusing on the frequency of AE and the clinical data sources used.
We conducted a systematic review by searching three electronic bibliographic databases targeting observational prospective active pharmacovigilance studies, phase IV clinical trials for post-marketing safety surveillance, and interventional studies assessing active pharmacovigilance strategies, focusing on individuals exposed to systemic antiviral agents.
We included 36 primary studies, predominantly using Drug Event Monitoring (DEM), with a minority employing sentinel sites and registries. Human immunodeficiency virus (HIV) was the most common condition, with the majority using DEM. Within the DEM, there was a wide range of incidences of patients experiencing at least one AE, and most of these studies used one or two data sources. Sentinel site studies were less common, with two on hepatitis C virus (HCV) and one on HIV, each relying on one or two data sources. The single study using a registry focusing on HIV therapy reported using just one data source. Patient interviews were the most common data source, followed by medical records and laboratory tests. The quality of the studies was considered 'good' in 18/36, 'fair' in 1/36, and 'poor' in 17/36 studies.
DEM was the predominant pharmacovigilance strategy, employing multiple data sources, and appears to increase the likelihood of detecting higher AE incidence. Establishing such a framework would facilitate a more detailed and consistent approach across different studies and settings.
在真实临床环境中,抗病毒药物的安全性至关重要,因为上市前研究通常无法捕捉到所有的不良反应(AE)。积极的药物警戒策略对于全面检测和描述这些 AE 至关重要。
本研究旨在确定和描述在真实临床环境中用于接受全身抗病毒药物治疗的患者的主动药物警戒策略,重点关注不良反应的频率和使用的临床数据源。
我们通过搜索三个电子文献数据库,针对观察性前瞻性主动药物警戒研究、上市后安全性监测的 IV 期临床试验以及评估主动药物警戒策略的干预性研究,进行了系统评价,重点关注暴露于全身抗病毒药物的个体。
我们纳入了 36 项主要研究,主要采用药物事件监测(DEM),少数采用哨点和登记处。人类免疫缺陷病毒(HIV)是最常见的疾病,大多数研究采用 DEM。在 DEM 中,患者至少经历一次不良反应的发生率差异很大,大多数研究仅使用了一个或两个数据源。哨点研究较少,有两项针对丙型肝炎病毒(HCV)的研究和一项针对 HIV 的研究,每项研究都依赖于一个或两个数据源。唯一一项关注 HIV 治疗的登记研究仅使用了一个数据源。患者访谈是最常用的数据源,其次是病历和实验室检查。36 项研究中有 18 项被认为质量“良好”,1 项为“中等”,17 项为“较差”。
DEM 是主要的药物警戒策略,使用多个数据源,似乎增加了检测更高不良反应发生率的可能性。建立这样的框架将有助于在不同的研究和环境中采用更详细和一致的方法。